The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
A user shared their 1.5-year hair restoration journey, successfully using mesenchymal stem cell therapy, Platelet Rich Plasma (PRP) injections, and a topical compound of finasteride and minoxidil, avoiding a hair transplant and oral finasteride. They experienced significant hair regrowth, particularly crediting the stem cell therapy for quick initial results.
Vitamin C mixed with shampoo stopped shedding and promoted hair regrowth after 1.5 years. Both the person and their wife experienced significant hair loss reduction with this method.
The user experienced significant hair regrowth using dermarolling, peppermint essential oil, rosemary carrier oil, finasteride, dutasteride, biotin, vitamin E, spirulina, fish oil, and a protein-rich diet. The oral versions of finasteride and dutasteride were noted as more effective.
The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.
The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.
A 30-year-old with Norwood 3V hair loss uses finasteride 1.25 mg every other day and Minoxidil (Regaine 5%) twice daily, experiencing no side effects with the current regimen. The front hairline remains unchanged, but the crown appears better in certain lighting.
RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.
PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.
The conversation is about whether doctors are offering hair transplants using verteporfin. Dr. Bargouthi in Jordan and Dr. Bloxham in New York are currently conducting trials on it.
New hair loss treatments like GT20029, Clascoterone, and PP405 are being discussed, with concerns about how to apply multiple topicals alongside existing treatments like minoxidil and finasteride. Suggestions include creating a routine, mixing treatments, or minimizing redundancy in treatment stacks.
PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.
The user shared their positive experience with hair regrowth using a minoxidil and finasteride spray, along with occasional microneedling, and encouraged others to try it. Despite skepticism from some users about a possible hair transplant, the user insisted their results were solely from the treatment.
Hair cloning claims by Dr. Gho are widely considered a scam, with skepticism about the effectiveness of his hair stem cell transplantation. Users suggest that if it were effective, wealthy individuals would opt for it over traditional methods like FUE transplants.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.
The conversation is about someone's progress with hair loss treatment using a combination of topical finasteride and minoxidil, and dermastamping once a week. They are considering increasing the dermastamp needle size from 1.25mm to 1.5mm.
Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.
GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.
User suggests rotating scalp 180 degrees to address hair loss. Others discuss sanity, ethics, and similar procedures like scalp reduction and hair transplants.
High-frequency wands for hair regrowth are discussed, with mixed reviews; one user found them ineffective and added finasteride. Another user called the wands a scam.
The user is using a routine involving microneedling, Minoxidil with tretinoin, a red light cap, scalp massages, Nizoral shampoo, and essence oil shampoo to address hair loss, with visible progress noted. They are considering topical finasteride or dutasteride if progress slows but are cautious due to past side effects.
The post discusses hair regrowth progress after 3 months of using Minoxidil four times a week, dermarolling twice a week, and using an anti-gray shampoo. The conversation includes speculation about the effectiveness of the shampoo, with some users noting visible darkening and growth of hair.
Using a blunt tip syringe for applying hair loss treatments like Minoxidil provides better scalp coverage than droppers. Users discuss the benefits of liquid over foam and share tips for effective application.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.